Sure, new indications are great. It potentially expands the pipeline and signals that the drug could be used for multiple applications. But in this current risk off environment I am absolutely not surprised it had no affect on the price as this is not company making news. Focus is on the trial and always has been.
I have no doubt the trial will commence at some stage and as another member said I also wouldn't be surprised if it was delayed due to current global circumstance. That's fine.
What I really want to know is what route they plan to take with regards to the $14m outstanding to get this trial to futility. This question has been lingering since the failed retail offer.
Then the other question for down the track is how long it will take to recruit patients and when the last patient is dosed so we can get an approximate timeline on when to expect futility results.
ANP Price at posting:
8.5¢ Sentiment: None Disclosure: Held
